Cargando…

Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma

PURPOSE: Genomic testing has increased the quantity of information available to oncologists. Unfortunately, many identified sequence alterations are variants of unknown significance (VUSs), which thus limit the clinician’s ability to use these findings to inform treatment. We applied a combination o...

Descripción completa

Detalles Bibliográficos
Autores principales: Egan, Jan B., Marks, David L., Hogenson, Tara L., Vrabel, Anne M., Sigafoos, Ashley N., Tolosa, Ezequiel J., Carr, Ryan M., Safgren, Stephanie L., Enriquez Hesles, Elisa, Almada, Luciana L., Romecin-Duran, Paola A., Iguchi, Eriko, Ala’Aldeen, Aryan, Kocher, Jean-Pierre A., Oliver, Gavin R., Prodduturi, Naresh, Mead, David W., Hossain, Asif, Huneke, Norine E., Tagtow, Colleen M., Ailawadhi, Sikander, Ansell, Stephen M., Banck, Michaela S., Bryce, Alan H., Carballido, Estrella M., Chanan-Khan, Asher A., Curtis, Kelly K., Resnik, Ernesto, Gawryletz, Chelsea D., Go, Ronald S., Halfdanarson, Thorvardur R., Ho, Thai H., Joseph, Richard W., Kapoor, Prashant, Mansfield, Aaron S., Meurice, Nathalie, Nageswara Rao, Amulya A., Nowakowski, Grzegorz S., Pardanani, Animesh, Parikh, Sameer A., Cheville, John C., Feldman, Andrew L., Ramanathan, Ramesh K., Robinson, Steven I., Tibes, Raoul, Finnes, Heidi D., McCormick, Jennifer B., McWilliams, Robert R., Jatoi, Aminah, Patnaik, Mrinal M., Silva, Alvin C., Wieben, Eric D., McAllister, Tammy M., Rumilla, Kandelaria M., Kerr, Sarah E., Lazaridis, Konstantinos N., Farrugia, Gianrico, Stewart, A. Keith, Clark, Karl J., Kennedy, Eileen J., Klee, Eric W., Borad, Mitesh J., Fernandez-Zapico, Martin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369924/
https://www.ncbi.nlm.nih.gov/pubmed/30761385
http://dx.doi.org/10.1200/PO.17.00018
_version_ 1783394270740217856
author Egan, Jan B.
Marks, David L.
Hogenson, Tara L.
Vrabel, Anne M.
Sigafoos, Ashley N.
Tolosa, Ezequiel J.
Carr, Ryan M.
Safgren, Stephanie L.
Enriquez Hesles, Elisa
Almada, Luciana L.
Romecin-Duran, Paola A.
Iguchi, Eriko
Ala’Aldeen, Aryan
Kocher, Jean-Pierre A.
Oliver, Gavin R.
Prodduturi, Naresh
Mead, David W.
Hossain, Asif
Huneke, Norine E.
Tagtow, Colleen M.
Ailawadhi, Sikander
Ansell, Stephen M.
Banck, Michaela S.
Bryce, Alan H.
Carballido, Estrella M.
Chanan-Khan, Asher A.
Curtis, Kelly K.
Resnik, Ernesto
Gawryletz, Chelsea D.
Go, Ronald S.
Halfdanarson, Thorvardur R.
Ho, Thai H.
Joseph, Richard W.
Kapoor, Prashant
Mansfield, Aaron S.
Meurice, Nathalie
Nageswara Rao, Amulya A.
Nowakowski, Grzegorz S.
Pardanani, Animesh
Parikh, Sameer A.
Cheville, John C.
Feldman, Andrew L.
Ramanathan, Ramesh K.
Robinson, Steven I.
Tibes, Raoul
Finnes, Heidi D.
McCormick, Jennifer B.
McWilliams, Robert R.
Jatoi, Aminah
Patnaik, Mrinal M.
Silva, Alvin C.
Wieben, Eric D.
McAllister, Tammy M.
Rumilla, Kandelaria M.
Kerr, Sarah E.
Lazaridis, Konstantinos N.
Farrugia, Gianrico
Stewart, A. Keith
Clark, Karl J.
Kennedy, Eileen J.
Klee, Eric W.
Borad, Mitesh J.
Fernandez-Zapico, Martin E.
author_facet Egan, Jan B.
Marks, David L.
Hogenson, Tara L.
Vrabel, Anne M.
Sigafoos, Ashley N.
Tolosa, Ezequiel J.
Carr, Ryan M.
Safgren, Stephanie L.
Enriquez Hesles, Elisa
Almada, Luciana L.
Romecin-Duran, Paola A.
Iguchi, Eriko
Ala’Aldeen, Aryan
Kocher, Jean-Pierre A.
Oliver, Gavin R.
Prodduturi, Naresh
Mead, David W.
Hossain, Asif
Huneke, Norine E.
Tagtow, Colleen M.
Ailawadhi, Sikander
Ansell, Stephen M.
Banck, Michaela S.
Bryce, Alan H.
Carballido, Estrella M.
Chanan-Khan, Asher A.
Curtis, Kelly K.
Resnik, Ernesto
Gawryletz, Chelsea D.
Go, Ronald S.
Halfdanarson, Thorvardur R.
Ho, Thai H.
Joseph, Richard W.
Kapoor, Prashant
Mansfield, Aaron S.
Meurice, Nathalie
Nageswara Rao, Amulya A.
Nowakowski, Grzegorz S.
Pardanani, Animesh
Parikh, Sameer A.
Cheville, John C.
Feldman, Andrew L.
Ramanathan, Ramesh K.
Robinson, Steven I.
Tibes, Raoul
Finnes, Heidi D.
McCormick, Jennifer B.
McWilliams, Robert R.
Jatoi, Aminah
Patnaik, Mrinal M.
Silva, Alvin C.
Wieben, Eric D.
McAllister, Tammy M.
Rumilla, Kandelaria M.
Kerr, Sarah E.
Lazaridis, Konstantinos N.
Farrugia, Gianrico
Stewart, A. Keith
Clark, Karl J.
Kennedy, Eileen J.
Klee, Eric W.
Borad, Mitesh J.
Fernandez-Zapico, Martin E.
author_sort Egan, Jan B.
collection PubMed
description PURPOSE: Genomic testing has increased the quantity of information available to oncologists. Unfortunately, many identified sequence alterations are variants of unknown significance (VUSs), which thus limit the clinician’s ability to use these findings to inform treatment. We applied a combination of in silico prediction and molecular modeling tools and laboratory techniques to rapidly define actionable VUSs. MATERIALS AND METHODS: Exome sequencing was conducted on 308 tumors from various origins. Most single nucleotide alterations within gene coding regions were VUSs. These VUSs were filtered to identify a subset of therapeutically targetable genes that were predicted with in silico tools to be altered in function by their variant sequence. A subset of receptor tyrosine kinase VUSs was characterized by laboratory comparison of each VUS versus its wild-type counterpart in terms of expression and signaling activity. RESULTS: The study identified 4,327 point mutations of which 3,833 were VUSs. Filtering for mutations in genes that were therapeutically targetable and predicted to affect protein function reduced these to 522 VUSs of interest, including a large number of kinases. Ten receptor tyrosine kinase VUSs were selected to explore in the laboratory. Of these, seven were found to be functionally altered. Three VUSs (FGFR2 F276C, FGFR4 R78H, and KDR G539R) showed increased basal or ligand-stimulated ERK phosphorylation compared with their wild-type counterparts, which suggests that they support transformation. Treatment of a patient who carried FGFR2 F276C with an FGFR inhibitor resulted in significant and sustained tumor response with clinical benefit. CONCLUSION: The findings demonstrate the feasibility of rapid identification of the biologic relevance of somatic mutations, which thus advances clinicians’ ability to make informed treatment decisions.
format Online
Article
Text
id pubmed-6369924
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-63699242019-02-11 Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma Egan, Jan B. Marks, David L. Hogenson, Tara L. Vrabel, Anne M. Sigafoos, Ashley N. Tolosa, Ezequiel J. Carr, Ryan M. Safgren, Stephanie L. Enriquez Hesles, Elisa Almada, Luciana L. Romecin-Duran, Paola A. Iguchi, Eriko Ala’Aldeen, Aryan Kocher, Jean-Pierre A. Oliver, Gavin R. Prodduturi, Naresh Mead, David W. Hossain, Asif Huneke, Norine E. Tagtow, Colleen M. Ailawadhi, Sikander Ansell, Stephen M. Banck, Michaela S. Bryce, Alan H. Carballido, Estrella M. Chanan-Khan, Asher A. Curtis, Kelly K. Resnik, Ernesto Gawryletz, Chelsea D. Go, Ronald S. Halfdanarson, Thorvardur R. Ho, Thai H. Joseph, Richard W. Kapoor, Prashant Mansfield, Aaron S. Meurice, Nathalie Nageswara Rao, Amulya A. Nowakowski, Grzegorz S. Pardanani, Animesh Parikh, Sameer A. Cheville, John C. Feldman, Andrew L. Ramanathan, Ramesh K. Robinson, Steven I. Tibes, Raoul Finnes, Heidi D. McCormick, Jennifer B. McWilliams, Robert R. Jatoi, Aminah Patnaik, Mrinal M. Silva, Alvin C. Wieben, Eric D. McAllister, Tammy M. Rumilla, Kandelaria M. Kerr, Sarah E. Lazaridis, Konstantinos N. Farrugia, Gianrico Stewart, A. Keith Clark, Karl J. Kennedy, Eileen J. Klee, Eric W. Borad, Mitesh J. Fernandez-Zapico, Martin E. JCO Precis Oncol Original Reports PURPOSE: Genomic testing has increased the quantity of information available to oncologists. Unfortunately, many identified sequence alterations are variants of unknown significance (VUSs), which thus limit the clinician’s ability to use these findings to inform treatment. We applied a combination of in silico prediction and molecular modeling tools and laboratory techniques to rapidly define actionable VUSs. MATERIALS AND METHODS: Exome sequencing was conducted on 308 tumors from various origins. Most single nucleotide alterations within gene coding regions were VUSs. These VUSs were filtered to identify a subset of therapeutically targetable genes that were predicted with in silico tools to be altered in function by their variant sequence. A subset of receptor tyrosine kinase VUSs was characterized by laboratory comparison of each VUS versus its wild-type counterpart in terms of expression and signaling activity. RESULTS: The study identified 4,327 point mutations of which 3,833 were VUSs. Filtering for mutations in genes that were therapeutically targetable and predicted to affect protein function reduced these to 522 VUSs of interest, including a large number of kinases. Ten receptor tyrosine kinase VUSs were selected to explore in the laboratory. Of these, seven were found to be functionally altered. Three VUSs (FGFR2 F276C, FGFR4 R78H, and KDR G539R) showed increased basal or ligand-stimulated ERK phosphorylation compared with their wild-type counterparts, which suggests that they support transformation. Treatment of a patient who carried FGFR2 F276C with an FGFR inhibitor resulted in significant and sustained tumor response with clinical benefit. CONCLUSION: The findings demonstrate the feasibility of rapid identification of the biologic relevance of somatic mutations, which thus advances clinicians’ ability to make informed treatment decisions. American Society of Clinical Oncology 2017-08-01 /pmc/articles/PMC6369924/ /pubmed/30761385 http://dx.doi.org/10.1200/PO.17.00018 Text en © 2017 by American Society of Clinical Oncology http://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Reports
Egan, Jan B.
Marks, David L.
Hogenson, Tara L.
Vrabel, Anne M.
Sigafoos, Ashley N.
Tolosa, Ezequiel J.
Carr, Ryan M.
Safgren, Stephanie L.
Enriquez Hesles, Elisa
Almada, Luciana L.
Romecin-Duran, Paola A.
Iguchi, Eriko
Ala’Aldeen, Aryan
Kocher, Jean-Pierre A.
Oliver, Gavin R.
Prodduturi, Naresh
Mead, David W.
Hossain, Asif
Huneke, Norine E.
Tagtow, Colleen M.
Ailawadhi, Sikander
Ansell, Stephen M.
Banck, Michaela S.
Bryce, Alan H.
Carballido, Estrella M.
Chanan-Khan, Asher A.
Curtis, Kelly K.
Resnik, Ernesto
Gawryletz, Chelsea D.
Go, Ronald S.
Halfdanarson, Thorvardur R.
Ho, Thai H.
Joseph, Richard W.
Kapoor, Prashant
Mansfield, Aaron S.
Meurice, Nathalie
Nageswara Rao, Amulya A.
Nowakowski, Grzegorz S.
Pardanani, Animesh
Parikh, Sameer A.
Cheville, John C.
Feldman, Andrew L.
Ramanathan, Ramesh K.
Robinson, Steven I.
Tibes, Raoul
Finnes, Heidi D.
McCormick, Jennifer B.
McWilliams, Robert R.
Jatoi, Aminah
Patnaik, Mrinal M.
Silva, Alvin C.
Wieben, Eric D.
McAllister, Tammy M.
Rumilla, Kandelaria M.
Kerr, Sarah E.
Lazaridis, Konstantinos N.
Farrugia, Gianrico
Stewart, A. Keith
Clark, Karl J.
Kennedy, Eileen J.
Klee, Eric W.
Borad, Mitesh J.
Fernandez-Zapico, Martin E.
Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
title Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
title_full Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
title_fullStr Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
title_full_unstemmed Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
title_short Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
title_sort molecular modeling and functional analysis of exome sequencing–derived variants of unknown significance identify a novel, constitutively active fgfr2 mutant in cholangiocarcinoma
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369924/
https://www.ncbi.nlm.nih.gov/pubmed/30761385
http://dx.doi.org/10.1200/PO.17.00018
work_keys_str_mv AT eganjanb molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT marksdavidl molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT hogensontaral molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT vrabelannem molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT sigafoosashleyn molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT tolosaezequielj molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT carrryanm molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT safgrenstephaniel molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT enriquezhesleselisa molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT almadalucianal molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT romecinduranpaolaa molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT iguchieriko molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT alaaldeenaryan molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT kocherjeanpierrea molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT olivergavinr molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT prodduturinaresh molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT meaddavidw molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT hossainasif molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT hunekenorinee molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT tagtowcolleenm molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT ailawadhisikander molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT ansellstephenm molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT banckmichaelas molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT brycealanh molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT carballidoestrellam molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT chanankhanashera molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT curtiskellyk molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT resnikernesto molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT gawryletzchelsead molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT goronalds molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT halfdanarsonthorvardurr molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT hothaih molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT josephrichardw molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT kapoorprashant molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT mansfieldaarons molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT meuricenathalie molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT nageswararaoamulyaa molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT nowakowskigrzegorzs molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT pardananianimesh molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT parikhsameera molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT chevillejohnc molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT feldmanandrewl molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT ramanathanrameshk molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT robinsonsteveni molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT tibesraoul molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT finnesheidid molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT mccormickjenniferb molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT mcwilliamsrobertr molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT jatoiaminah molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT patnaikmrinalm molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT silvaalvinc molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT wiebenericd molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT mcallistertammym molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT rumillakandelariam molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT kerrsarahe molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT lazaridiskonstantinosn molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT farrugiagianrico molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT stewartakeith molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT clarkkarlj molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT kennedyeileenj molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT kleeericw molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT boradmiteshj molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma
AT fernandezzapicomartine molecularmodelingandfunctionalanalysisofexomesequencingderivedvariantsofunknownsignificanceidentifyanovelconstitutivelyactivefgfr2mutantincholangiocarcinoma